Addex Therapeutics Ltd (ADXN) Earnings History
Net Loss20 years of earnings data (2006–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Addex Therapeutics Ltd (ADXN) Earnings Overview
As of September 26, 2026, Addex Therapeutics Ltd (ADXN) reported trailing twelve-month net income of -$7M, reflecting -181.9% year-over-year growth. The company earned $-4.88 per diluted share over the past four quarters, with a net profit margin of -22448.4%.
Looking at the long-term picture, ADXN's historical earnings data spans multiple years. The company achieved its highest annual net income of $7M in fiscal 2024.
Addex Therapeutics Ltd is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ACAD ($380M net income, 36.5% margin), INVA ($357M net income, 63.8% margin), PRAX (-$339M net income), ADXN has room to improve margins relative to the peer group. Compare ADXN vs ACAD →
ADXN Earnings vs Peers
Earnings metrics vs comparable public companies
ADXN Historical Earnings Data (2006–2025)
20 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$7M | -195.4% | -$3M | $-6.88 | -22448.4% | -9390.8% |
| 2024 | $7M | +166.8% | -$3M | $8.40 | 1746.0% | -681.8% |
| 2023 | -$11M | +49.3% | -$2M | $-16.80 | -654.5% | -139.1% |
| 2022 | -$21M | -35.5% | -$11M | $-55.20 | -1462.6% | -741.0% |
| 2021 | -$15M | -19.4% | -$16M | $-54.00 | -526.4% | -531.7% |
| 2020 | -$13M | +13.0% | -$12M | $-57.60 | -355.9% | -338.9% |
| 2019 | -$15M | -798.6% | -$15M | $-67.20 | -535.0% | -528.6% |
| 2018 | -$2M | +49.9% | -$1M | $-8.47 | -27.2% | -23.6% |
| 2017 | -$3M | -4.2% | -$3M | $-30.00 | -656.2% | -647.1% |
| 2016 | -$3M | +25.1% | -$3M | $-33.60 | -18174.1% | -18059.9% |
| 2015 | -$4M | -136.9% | -$4M | $-46.80 | -10432.0% | -9597.6% |
| 2014 | -$2M | +87.7% | -$2M | $-21.60 | -2078.2% | -2103.7% |
| 2013 | -$14M | +45.7% | -$14M | $-192.00 | -15760.5% | -15757.0% |
| 2012 | -$27M | +14.5% | -$27M | $-403.20 | -21976.8% | -22306.2% |
| 2011 | -$31M | +7.4% | -$31M | $-3016.80 | -1102.9% | -1097.0% |
| 2010 | -$34M | +21.2% | -$34M | $-4094.40 | -1703.3% | -1700.9% |
| 2009 | -$43M | -93.5% | -$43M | $-5360.40 | -1043.6% | -1052.5% |
| 2008 | -$22M | +37.1% | -$25M | $-2769.60 | -82.3% | -92.8% |
| 2007 | -$35M | -70.8% | -$38M | $-5035.20 | -7205.5% | -7726.3% |
| 2006 | -$21M | - | -$21M | $-51.60 | -433.5% | -441.0% |
Download Data
Export ADXN earnings history in CSV or JSON format
Free sign-in required to download data
ADXN Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
20+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ADXN — Frequently Asked Questions
Quick answers to the most common questions about buying ADXN stock.
What is ADXN earnings per share (EPS)?
ADXN trailing twelve-month (TTM) diluted EPS is $-4.88, reflecting -181.9% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2006 to 2025 is available in the table on this page.
What is Addex Therapeutics Ltd's net income?
Addex Therapeutics Ltd (ADXN) trailing twelve-month net income is $-7M as of 2025. Earnings declined -181.9% year-over-year.
Is ADXN profitable?
ADXN is not currently profitable on a TTM basis, reporting a net loss of $-7M. Net margin is -22448.4%. Investors should monitor for a return to profitability.
What is ADXN's earnings growth rate?
ADXN compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2006 to 2025.
What are ADXN's profit margins?
Addex Therapeutics Ltd net profit margin is -22448.4%, operating margin is -9390.8%, and gross margin is +100.0%. Below-average margins reflect competitive or cost pressures. Return on Equity is -93.2%.
Is ADXN growing earnings?
ADXN earnings are declining — EPS fell -181.9% year-over-year. TTM net income dropped to $-7M. This contrasts with the 5-year CAGR of N/A.
What was ADXN's best earnings year?
Addex Therapeutics Ltd's highest annual net income on record is $7M, achieved in fiscal year 2024. Earnings history on this page spans 2006 to 2025 and includes all annual and quarterly figures.
What were ADXN's earnings last quarter?
ADXN's most recent reported quarter was Q1 2026. Net income was $-2M with diluted EPS of $-1.20. For a full breakdown of all quarters, see the quarterly earnings table on this page.